Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Multiple Dose Regimens of MT-3724 With Gemcitabine and Oxaliplatin for the Treatment of Subjects With Relapsed or Refractory CD20-positive B Cell Non-Hodgkin's Lymphoma

Trial Profile

Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Multiple Dose Regimens of MT-3724 With Gemcitabine and Oxaliplatin for the Treatment of Subjects With Relapsed or Refractory CD20-positive B Cell Non-Hodgkin's Lymphoma

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 27 Jun 2018

At a glance

  • Drugs MT 3724 (Primary) ; Gemcitabine; Oxaliplatin
  • Indications Diffuse large B cell lymphoma; Non-Hodgkin's lymphoma
  • Focus Adverse reactions; Registrational
  • Sponsors Molecular Templates
  • Most Recent Events

    • 18 Jun 2018 Planned initiation date changed from 30 May 2018 to 15 Jul 2018.
    • 05 Jan 2018 This trial is expected to begin in 2H 2018 according to a Molecular Templates media release.
    • 24 Oct 2017 According to a Molecular Templates media release, this trial is expected to begin in 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top